JP2005507380A5 - - Google Patents

Download PDF

Info

Publication number
JP2005507380A5
JP2005507380A5 JP2003521229A JP2003521229A JP2005507380A5 JP 2005507380 A5 JP2005507380 A5 JP 2005507380A5 JP 2003521229 A JP2003521229 A JP 2003521229A JP 2003521229 A JP2003521229 A JP 2003521229A JP 2005507380 A5 JP2005507380 A5 JP 2005507380A5
Authority
JP
Japan
Prior art keywords
alkyl
cyano
substituted
formula
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003521229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005507380A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/008953 external-priority patent/WO2003016306A1/en
Publication of JP2005507380A publication Critical patent/JP2005507380A/ja
Publication of JP2005507380A5 publication Critical patent/JP2005507380A5/ja
Withdrawn legal-status Critical Current

Links

JP2003521229A 2001-08-13 2002-08-09 Hiv阻害性ピリミジン誘導体 Withdrawn JP2005507380A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01203090 2001-08-13
EP02077748 2002-06-10
PCT/EP2002/008953 WO2003016306A1 (en) 2001-08-13 2002-08-09 Hiv inhibiting pyrimidines derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009259107A Division JP5247661B2 (ja) 2001-08-13 2009-11-12 Hiv阻害性ピリミジン誘導体

Publications (2)

Publication Number Publication Date
JP2005507380A JP2005507380A (ja) 2005-03-17
JP2005507380A5 true JP2005507380A5 (enExample) 2006-01-05

Family

ID=26076978

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003521229A Withdrawn JP2005507380A (ja) 2001-08-13 2002-08-09 Hiv阻害性ピリミジン誘導体
JP2009259107A Expired - Lifetime JP5247661B2 (ja) 2001-08-13 2009-11-12 Hiv阻害性ピリミジン誘導体
JP2011134088A Expired - Lifetime JP4838396B2 (ja) 2001-08-13 2011-06-16 Hiv阻害性ピリミジン誘導体
JP2011135468A Expired - Lifetime JP5539927B2 (ja) 2001-08-13 2011-06-17 Hiv阻害性ピリミジン誘導体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009259107A Expired - Lifetime JP5247661B2 (ja) 2001-08-13 2009-11-12 Hiv阻害性ピリミジン誘導体
JP2011134088A Expired - Lifetime JP4838396B2 (ja) 2001-08-13 2011-06-16 Hiv阻害性ピリミジン誘導体
JP2011135468A Expired - Lifetime JP5539927B2 (ja) 2001-08-13 2011-06-17 Hiv阻害性ピリミジン誘導体

Country Status (37)

Country Link
US (8) US7125879B2 (enExample)
EP (3) EP1419152B1 (enExample)
JP (4) JP2005507380A (enExample)
KR (2) KR100817453B1 (enExample)
CN (2) CN101816658B (enExample)
AP (1) AP1610A (enExample)
AR (1) AR036387A1 (enExample)
AT (1) ATE517891T1 (enExample)
AU (1) AU2002329238C1 (enExample)
BE (3) BE2012C020I2 (enExample)
BR (3) BR122015023612B8 (enExample)
CA (1) CA2452217C (enExample)
CY (4) CY1112331T1 (enExample)
DE (1) DE122012000038I1 (enExample)
DK (2) DK1419152T3 (enExample)
EA (1) EA006656B1 (enExample)
EG (1) EG24684A (enExample)
ES (3) ES2923581T3 (enExample)
FR (3) FR12C0035I2 (enExample)
HR (3) HRP20040096B1 (enExample)
HU (5) HU231274B1 (enExample)
IL (2) IL160328A0 (enExample)
JO (1) JO3429B1 (enExample)
LT (3) LT3808743T (enExample)
LU (2) LU92001I2 (enExample)
MX (1) MXPA04001401A (enExample)
MY (1) MY189572A (enExample)
NO (3) NO327639B1 (enExample)
NZ (1) NZ530951A (enExample)
OA (1) OA12652A (enExample)
PA (1) PA8552901A1 (enExample)
PL (2) PL216398B1 (enExample)
PT (1) PT1419152E (enExample)
SI (2) SI3808743T1 (enExample)
UA (1) UA78221C2 (enExample)
WO (1) WO2003016306A1 (enExample)
ZA (1) ZA200401159B (enExample)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
KR20040090979A (ko) 2002-03-13 2004-10-27 얀센 파마슈티카 엔.브이. 히스톤 데아세틸레이즈의 신규한 억제제
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
PL208533B1 (pl) * 2002-08-09 2011-05-31 Janssen Pharmaceutica Nv Sposób otrzymywania 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu oraz sposób otrzymywania związku pośredniego
EA200500721A1 (ru) * 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
KR20050105190A (ko) 2003-02-07 2005-11-03 얀센 파마슈티카 엔.브이. Hiv를 저해하는 1,2,4-트리아진
CL2004000192A1 (es) * 2003-02-07 2005-03-18 Janssen Pharmaceutica Nv Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
US20060172010A1 (en) 2003-07-17 2006-08-03 Gael Lamoureux Process for preparing particles containing an antiviral
JP4886511B2 (ja) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ, インコーポレイテッド 2,4−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
BR122019017579B8 (pt) * 2003-08-15 2021-07-27 Novartis Ag 2,4-pirimidinadiaminas, seus usos, combinação e composição farmacêutica
TWI365744B (en) * 2003-09-03 2012-06-11 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
EA009734B1 (ru) * 2003-09-25 2008-02-28 Янссен Фармацевтика Н.В. Производные пурина, ингибирующие репликацию вич
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
EP1781639B1 (en) 2004-07-28 2012-01-25 Janssen Pharmaceutica NV Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
JP5031564B2 (ja) 2004-08-10 2012-09-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Hiv抑制1,2,4−トリアジン−6−オン誘導体
KR101241716B1 (ko) 2004-08-25 2013-03-08 아디아 바이오사이언스즈 인크. HIV 역 전사 효소의 억제제로서 S-트리아졸릴 α-메르캅토아세트아닐리드
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
EP1789139B1 (en) * 2004-09-02 2012-03-21 Janssen Pharmaceutica NV Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl amino -2-pyrimidinyl amino benzonitrile
PT1632232E (pt) * 2004-09-02 2011-08-02 Janssen Pharmaceutica Nv Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
WO2006024668A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
SI1789139T1 (sl) * 2004-09-02 2012-08-31 Janssen Pharmaceutica Nv Fumarat 4-((4-((4-(2-cianoetenil)-2,6-dimetifenil amino-2-pirimidinil amino benzonitrila
UA92469C2 (en) * 2004-09-02 2010-11-10 Янссен Фармацевтика Н.В. Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
WO2006034341A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
AR051026A1 (es) 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
CA2580855A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
ES2380631T3 (es) 2004-09-30 2012-05-17 Tibotec Pharmaceuticals Pirimidinas sustituidas en posición 5 inhibidoras de VIH
BRPI0516746A (pt) 2004-09-30 2008-09-23 Tibotec Pharm Ltd 5-heterociclil pirimidinas para inibição de hiv
KR20070057798A (ko) * 2004-09-30 2007-06-07 티보텍 파마슈티칼즈 리미티드 Hiv를 저해하는 5-탄소환 또는 복소환으로 치환된피리미딘
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
CN101115761B (zh) 2005-01-19 2012-07-18 里格尔药品股份有限公司 2,4-嘧啶二胺化合物的前药及其应用
US7906511B2 (en) 2005-03-31 2011-03-15 Santen Pharmaceutical Co., Ltd. Cyclic compound having pyrimidinylalkylthio group
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Hiv-感染之預防
EP1877411B9 (en) 2005-05-05 2012-08-29 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
CA2609716C (en) * 2005-05-26 2014-10-14 Tibotec Pharmaceuticals Ltd. Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitrile
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
AU2006254840B2 (en) 2005-06-08 2012-08-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
NZ567851A (en) 2005-11-01 2011-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
JP5247470B2 (ja) 2006-01-19 2013-07-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体
RS52821B2 (sr) * 2006-01-20 2021-07-30 Janssen Sciences Ireland Unlimited Co Dugotrajno tretiranje hiv-infekcije sa tcm278
HRP20100696T1 (hr) 2006-03-30 2011-01-31 Tibotec Pharmaceuticals Hiv inhibirajuci 5-(hidroksimetilen i aminometilen) supstituirani pirimidini
ES2465666T3 (es) 2006-03-30 2014-06-06 Janssen R&D Ireland Pirimidinas 5-amido-sustituidas inhibidoras del HIV
AU2016219555B2 (en) * 2006-06-23 2017-08-10 Janssen Sciences Ireland Uc Aqueous suspensions of TMC278
UA97641C2 (xx) * 2006-06-23 2012-03-12 Тиботек Фармасьютикелз Лтд. Водна суспензія 4-$$4-$$4-(2-ціаноетеніл)-2,6-диметилфеніл]аміно]-2-піримідиніл]аміно]бензонітрилу (tmc278)$водная суспензия 4-$$4-$$4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила (тмс278)
AU2014200819B2 (en) * 2006-06-23 2016-05-26 Janssen Sciences Ireland Uc Aqueous suspensions of TMC278
EP2132211A4 (en) 2006-11-09 2011-12-07 Ardea Biosciences Inc 4-CYANPHENYLAMINO-SUBSTITUTED BICYCLIC AND HETEROCYCLIC COMPOUNDS AS AN HIV HEMMER
KR101364277B1 (ko) 2006-12-08 2014-02-21 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
AU2007332654B2 (en) * 2006-12-13 2013-06-20 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
ES2523863T3 (es) 2006-12-29 2014-12-02 Janssen R&D Ireland Pirimidinas 5,6-sustituidas inhibidoras del VIH
BRPI0720858B8 (pt) 2006-12-29 2021-05-25 Janssen R & D Ireland pirimidinas 6-substituídas inibidoras de hiv e composição farmacêutica que as compreende
JP2010518014A (ja) 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な2−アミノピリジン誘導体
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
DK2146779T3 (en) * 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
CN101679294B (zh) 2007-05-30 2012-08-08 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
CA2693044C (en) * 2007-07-12 2017-03-14 Tibotec Pharmaceuticals Crystalline form of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
CN101407476B (zh) 2007-10-12 2012-07-18 中国人民解放军军事医学科学院毒物药物研究所 作为非核苷类hiv逆转录酶抑制剂的间二芳烃-多取代苯胺类化合物、其制备方法及用途
DK2217577T3 (da) 2007-11-27 2014-10-20 Ardea Biosciences Inc Hidtil ukendte forbindelser og præparater og fremgangsmåder til anvendelse deraf
ES2389752T3 (es) 2007-12-14 2012-10-31 Ardea Biosciences, Inc. Inhibidores de la transcriptasa inversa
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
SG10201510696RA (en) 2008-06-27 2016-01-28 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
JP5631310B2 (ja) 2008-07-23 2014-11-26 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 三環式ピラゾロピリジンキナーゼ阻害剤
EP2318407B1 (en) 2008-07-23 2013-01-02 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
CA2732765A1 (en) * 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
WO2010040275A1 (zh) * 2008-10-09 2010-04-15 中国人民解放军军事医学科学院毒物药物研究所 作为非核苷类hiv逆转录酶抑制剂的2-(4-取代苯胺基)多取代吡啶类化合物、其制备方法及用途
CN101717364B (zh) * 2008-10-09 2014-08-13 中国人民解放军军事医学科学院毒物药物研究所 作为hiv逆转录酶抑制剂的吡啶类化合物及其制备方法和用途
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
NZ593950A (en) 2008-12-24 2013-08-30 Janssen R & D Ireland Implantable devices for treating hiv
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Egfr阻害剤及び疾患の治療方法
WO2010129668A1 (en) 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
MX2012008643A (es) 2010-01-27 2013-02-26 Vertex Pharma Inhibidores de cinasas de pirazolopiridinas.
RS54123B1 (sr) 2010-01-27 2015-12-31 Viiv Healthcare Company Terapeutska kombinacija koja sadrži dolutegravir, abacavir i lamivudine
US9067932B2 (en) 2010-01-27 2015-06-30 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
CN102869663A (zh) 2010-01-27 2013-01-09 沃泰克斯药物股份有限公司 吡唑并吡嗪激酶抑制剂
EP2536696A1 (en) * 2010-02-18 2012-12-26 Concert Pharmaceuticals Inc. Pyrimidine derivatives
US8367315B2 (en) * 2010-03-05 2013-02-05 Adan Rios Inactivation of reverse transcriptases by azido-diarylpyrimidines
MY160734A (en) 2010-08-10 2017-03-15 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
NZ710636A (en) 2010-11-01 2017-02-24 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
NZ610729A (en) 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
WO2012147091A2 (en) 2011-04-25 2012-11-01 Hetero Research Foundation Process for rilpivirine
US9981918B2 (en) 2011-08-30 2018-05-29 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2755959B1 (en) 2011-09-16 2018-05-16 Hetero Research Foundation Rilpivirine hydrochloride
CA2853498A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
EP2628732A1 (en) 2012-02-20 2013-08-21 Sandoz AG Novel crystalline form of rilpivirine hydrochloride
EP2604593A1 (en) 2011-12-14 2013-06-19 Sandoz AG Polymorph of Rilpivirine hydrochloride and its use as antiviral
WO2013087794A1 (en) 2011-12-14 2013-06-20 Sandoz Ag Polymorph of rilpivirine hydrochloride and its use as antiviral
BR112014022789B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
SMT201800571T1 (it) 2012-03-15 2019-01-11 Celgene Car Llc Sali di un inibitore di chinasi del recettore del fattore di crescita dell’epidermide
WO2013153161A2 (en) 2012-04-11 2013-10-17 Sandoz Ag Novel polymorph of rilpivirine hydrochloride
WO2013153162A1 (en) 2012-04-11 2013-10-17 Sandoz Ag Polymorph of rilpivirine hydrochloride
WO2013179105A1 (en) * 2012-06-01 2013-12-05 Laurus Labs Private Limited Improved process for preparation of rilpivirine and pharmaceutically acceptable salts thereof
ES2664094T3 (es) * 2012-07-12 2018-04-18 Hetero Research Foundation Procedimiento de preparación de rilpivirina utilizando un intermedio nuevo
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9914709B2 (en) 2013-06-21 2018-03-13 Yale University Compositions and methods of treating HIV-1 infections using same
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
KR20170026633A (ko) * 2014-07-17 2017-03-08 씨에이치디아이 파운데이션, 인코포레이티드 Hiv-관련 장애의 치료 방법 및 치료용 조성물
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
KR20170056702A (ko) 2014-09-26 2017-05-23 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 지효성 약제학적 조성물
CZ201532A3 (cs) 2015-01-21 2015-02-25 Zentiva, K.S. Způsob výroby vysoce čistého Rilpivirinu a jeho solí
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
EA201792592A1 (ru) 2015-06-30 2018-06-29 Джилид Сайэнс, Инк. Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
CZ2015579A3 (cs) 2015-08-27 2017-03-08 Zentiva, K.S. Krystalická forma A Rilpivirin Adipátu a způsob její přípravy
CN106187916B (zh) * 2016-07-04 2018-08-21 宜昌人福药业有限责任公司 一种有效去除利匹韦林异构体的方法
HUE064823T2 (hu) 2016-10-24 2024-04-28 Janssen Sciences Ireland Unlimited Co Diszpergálható készítmények
CN106749203B (zh) * 2016-11-28 2020-04-10 洛阳聚慧医药科技有限公司 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
CN106588696B (zh) * 2016-12-08 2018-12-25 西北师范大学 一种反式α,β-不饱和腈类化合物的制备方法
CN106905244B (zh) * 2017-02-27 2019-08-16 武汉工程大学 二芳基嘧啶-二酮酸类杂合型hiv-1抑制剂及其制备方法
EP3645003A4 (en) 2017-06-30 2021-03-10 VIIV Healthcare Company COMBINATION AND USES AND TREATMENTS THEREOF
CN112996795B (zh) 2018-09-18 2024-11-12 尼坎治疗公司 作为src同源-2磷酸酶抑制剂的稠合的三环衍生物
CN109293581B (zh) * 2018-09-21 2020-03-27 宜昌人福药业有限责任公司 一种制备盐酸利匹韦林异构体z和杂质x的方法及杂质x作为杀虫剂在农业中的应用
EP3870568B1 (en) 2018-10-25 2023-06-28 Minakem Process for the preparation of rilpivirine
BR112021026916A2 (pt) * 2019-07-03 2022-05-10 Janssen Sciences Ireland Unlimited Co Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina
CN110526873B (zh) * 2019-08-15 2022-09-16 复旦大学 氰乙烯基取代的苯并二芳基嘧啶类化合物及其制备方法和用途
CA3152105A1 (en) 2019-11-29 2021-06-03 Wai Yip Thomas Lee Composition including rilpivirine and use thereof for treating tumors or cancer
CN111004215B (zh) * 2019-12-22 2022-08-09 华北理工大学 2,4-取代嘧啶类衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN111217833B (zh) * 2020-02-21 2021-03-16 山东大学 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
WO2022000019A1 (en) * 2020-06-30 2022-01-06 University Of South Australia New therapeutic use of rilpivirine
CN112028836B (zh) * 2020-09-09 2021-12-07 山东大学 一种含有六元氮杂环的二芳基嘧啶类衍生物及其制备方法与应用
CN112010810B (zh) * 2020-09-09 2024-01-30 瑞阳制药股份有限公司 一锅法制备高纯度利匹韦林中间体的方法
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
TW202233192A (zh) 2020-11-17 2022-09-01 愛爾蘭商健生科學愛爾蘭無限公司 Hiv感染之治療或預防
CN112546969B (zh) * 2020-12-07 2022-12-23 安徽贝克制药股份有限公司 催化加氢连续生产装置和利托那韦中间体的制备方法
CN112778214A (zh) * 2021-01-13 2021-05-11 安徽贝克联合制药有限公司 用于合成利匹韦林的中间体、其合成方法和利匹韦林的合成方法
CN113105394A (zh) * 2021-03-08 2021-07-13 复旦大学 一种含芳杂环结构的联苯二芳基嘧啶类衍生物及其制备方法和应用
CN113461666A (zh) * 2021-05-06 2021-10-01 复旦大学 含芳杂环结构的联苯二芳基甲基嘧啶衍生物及其制备方法
CN113845515A (zh) * 2021-09-03 2021-12-28 复旦大学 一种含芳杂环结构的二甲基联苯二芳基嘧啶类衍生物及其制备方法和应用
AR127700A1 (es) 2021-11-17 2024-02-21 Janssen Sciences Ireland Unlimited Co Prueba de disolución
WO2023203255A1 (en) 2022-04-22 2023-10-26 Janssen Sciences Ireland Unlimited Company Freeze dried compositions
US20250268896A1 (en) 2022-04-22 2025-08-28 Janssen Sciences Ireland Unlimited Company Liquid compositions
TW202408527A (zh) 2022-05-17 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 治療或預防hiv感染(二)
TW202408526A (zh) 2022-05-17 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 治療或預防hiv感染(一)
CN115490642B (zh) * 2022-09-21 2024-11-15 山东大学 一种含醚键的二芳基嘧啶类化合物及其制备方法与应用
CN117343017A (zh) * 2023-09-28 2024-01-05 四川大学 含联芳基结构的卤代二芳基嘧啶类化合物及其制备方法和用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3953398A (en) * 1970-07-20 1976-04-27 The Goodyear Tire & Rubber Company Age resistant polymeric compositions
JPS63159316A (ja) * 1977-11-28 1988-07-02 アルキユサル インコーポレーテツド ピーテイワイ リミテツド 中性銅結合体を含む抗炎症組成物
DE2861560D1 (en) * 1977-11-28 1982-03-04 Barry Boettcher Complexes of bivalent copper, methods of preparation thereof and compositions containing said complexes
JPS5879920A (ja) * 1981-11-09 1983-05-13 Kanegafuchi Chem Ind Co Ltd 血小板凝集阻害剤
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0862463A1 (en) 1995-11-23 1998-09-09 Janssen Pharmaceutica N.V. Solid mixtures of cyclodextrins prepared via melt-extrusion
TW429256B (en) 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
JP3990808B2 (ja) * 1998-03-26 2007-10-17 Tdk株式会社 非水電解質電池用電極の製造方法
NZ506679A (en) * 1998-03-27 2002-11-26 Janssen Pharmaceutica Nv HIV inhibiting pyrimidine derivatives
BRPI9909191B8 (pt) * 1998-03-27 2021-07-06 Janssen Pharmaceutica Nv derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende
EP0945447A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
JP2000035628A (ja) * 1998-07-16 2000-02-02 Konica Corp ハロゲン化銀写真感光材料
DE69933680T2 (de) * 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
SK287269B6 (sk) * 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu, jeho použitie, spôsob jeho prípravy a farmaceutická kompozícia, kombinácia a produkt s jeho obsahom
KR20010102543A (ko) 1999-03-09 2001-11-15 로렌스 티. 마이젠헬더 항바이러스제로서의4-옥소-4,7-디히드로-티에노[2,3-b]피리딘-5-카르복스아미드
PT1169038E (pt) 1999-04-15 2012-10-26 Bristol Myers Squibb Co Inibidores cíclicos da proteína tirosina cinase
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
JP4919566B2 (ja) * 1999-09-24 2012-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗ウイルス組成物
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
MXPA02007957A (es) * 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
JP5230050B2 (ja) 2000-05-08 2013-07-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Hiv複製阻害剤
DK1282607T3 (en) 2000-05-08 2016-02-01 Janssen Pharmaceutica Nv Prodrugs of HIV replication inhibiting pyrimidines
US6596729B2 (en) * 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
CA2439820A1 (en) 2001-03-02 2002-09-12 Smithkline Beecham Corporation Benzophenones as inhibitors of reverse transcriptase
EP1373257B9 (en) * 2001-03-29 2008-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
US8101629B2 (en) * 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
CA2457526A1 (en) * 2001-08-29 2003-03-13 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2298510T3 (es) * 2002-05-03 2008-05-16 Janssen Pharmaceutica Nv Microemulsiones polimericas.
PL208533B1 (pl) 2002-08-09 2011-05-31 Janssen Pharmaceutica Nv Sposób otrzymywania 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu oraz sposób otrzymywania związku pośredniego
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
CL2004000192A1 (es) * 2003-02-07 2005-03-18 Janssen Pharmaceutica Nv Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
WO2011103559A1 (en) * 2010-02-22 2011-08-25 Nektar Therapeutics Oligomer modified diaromatic substituted compounds

Similar Documents

Publication Publication Date Title
JP2005507380A5 (enExample)
JP2009509961A5 (enExample)
AU2009304598B2 (en) S1P receptors modulators and their use thereof
JP5726190B2 (ja) タンパク質キナーゼ阻害剤としての化合物および組成物
JP2017537949A5 (enExample)
CA2516699A1 (en) Hiv replication inhibiting pyrimidines and triazines
JP2012532139A5 (enExample)
JP2004534774A5 (enExample)
JP2012528822A5 (enExample)
JP2013523897A5 (enExample)
JP2017516826A5 (enExample)
JP2012530713A5 (enExample)
JP2013528640A5 (enExample)
JP2017513955A5 (enExample)
JP2009523760A5 (enExample)
JP2002520416A5 (enExample)
JP2016527217A5 (enExample)
JP2012530056A5 (enExample)
JP2009522206A5 (enExample)
TW201105675A (en) Compounds and compositions for the treatment of parasitic diseases
JP2014500322A5 (enExample)
JP2007502293A5 (enExample)
RU2007108539A (ru) Производные 1, 2, 4-триазин-6-она, ингибирующие вич
JP2004514663A5 (enExample)
JP2005530811A5 (enExample)